aumolertinib: Clinical Trials

63 trials of aumolertinib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

32 unknown, 11 recruiting, 8 not yet recruiting, 6 active not recruiting. 34 Phase 2, 17 Phase 3, 9 Phase 1, 4 Not applicable, 1 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 234Unknown 20, Not yet recruiting 7, Recruiting 4, Active not recruiting 2, Withdrawn 1
Phase 317Unknown 6, Recruiting 5, Active not recruiting 4, Enrolling by invitation 1, Terminated 1
Phase 19Unknown 4, Completed 2, Recruiting 2, Not yet recruiting 1
Not applicable4Unknown 2, Not yet recruiting 1, Recruiting 1
Phase 41Unknown 1

Follow aumolertinib: new trials by email Literature Review of aumolertinib trials Research Report on aumolertinib

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
MRD-Guided Aumolertinib-Based Adjuvant Therapy for Resected EGFR-Mutant NSCLC
Aumolertinib, Pemetrexed, Carboplatin - Non-Small Cell Lung Cancer
Not applicableNot yet recruitingPeking University People's Hospital502026-11-012026-10-14
An Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer.
adebrelimab + SHR-A2009, paclitaxel or pemetrexed combined with carboplatin +adebrelimab, adebrelimab - Non-small Cell Lung Cancer
Phase 2Not yet recruitingSuzhou Suncadia Biopharmaceuticals Co., Ltd.6602026-10-302026-11-09
First-line Therapy With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor(EGFR-TKI) Combined With Trastuzumab Rezetecan for Advanced Non-small Cell Lung Cancer(NSCLC) Harboring EGFR Mutations Concomitant With Human Epidermal Growth Factor Receptor 2(HER2) Alterations
Almonertinib, Trastuzumab Rezetecan - Lung Cancer (NSCLC), EGFR Activating Mutation
Phase 2Not yet recruitingYongsheng Wang352026-09-092026-08-17
A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC
SHR-A2009 ; Aumolertinib, Aumolertinib - Non-small Cell Lung Cancer
Phase 3Active not recruitingSuzhou Suncadia Biopharmaceuticals Co., Ltd.5822025-10-302026-09-25
A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC
BL-B01D1, Almonertinib - Non-Small Cell Lung Cancer
Phase 2RecruitingSichuan University402025-06-252025-07-23
A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS Mutations
Almonertinib, Palbociclib - EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor
Phase 1 / Phase 2RecruitingSun Yat-sen University712025-06-092025-06-04
Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer
Aumolertinib, Osimertinib - Non Small Cell Lung Cancer
Phase 2Not yet recruitingPeking Union Medical College Hospital3162024-12-172024-12-30
A Study of Aumolertinib in European Participants With Non-Small Cell Lung Cancer
Aumolertinib - Non-Small Cell Lung Cancer
Phase 1RecruitingJiangsu Hansoh Pharmaceutical Co., Ltd.202024-12-052025-08-19
AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients With Baseline Brain Metastases
third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib) - NSCLC (Advanced Non-small Cell Lung Cancer), Brain Metastasases
RecruitingFudan University8002024-09-302024-11-12
Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.
gumarontinib, third-generation EGFR-TKI (Osimertinib, Almonertinib or Furmonertinib) - Non-small Cell Lung Cancer
Phase 2Not yet recruitingCancer Institute and Hospital, Chinese Academy of Medical Sciences912024-06-012024-06-11
Aumolertinib in EGFR-Mutant Resected Stage IB-IIIA NSCLC (AERESA).
Aumolertinib - Lung Cancer
Phase 2WithdrawnSun Yat-sen University2024-06-012024-12-10
Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Cancer
Almonertinib - Lung Cancer Non-small Cell Stage IV
Phase 2UnknownShanghai Pulmonary Hospital, Shanghai, China602024-06-012024-06-17
A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer
HS-20117, Aumolertinib - Non-Squamous Non-Small Cell Lung Cancer
Phase 2 / Phase 3RecruitingHansoh BioMedical R&D Company10802024-05-282025-08-01
Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC
almonertinib, Carboplatin, Nab paclitaxel - Non Small Cell Lung Cancer, EGFR Gene Mutation
Phase 2Active not recruitingGuangdong Provincial People's Hospital322024-04-012026-04-29
RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations
Disitamab Vedotin, third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib), pyrotinib - Non Small Cell Lung Cancer, ERBB2 Mutation-Related Tumors
Phase 2Not yet recruitingCancer Institute and Hospital, Chinese Academy of Medical Sciences1082024-02-012023-12-29
A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation
Combined therapy of anlotinib and aumolertinib - Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Not applicableRecruitingKunming Medical University302023-10-302023-10-26
Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung Cancer
Almonertinib - Lung Cancer Stage III
Phase 2 / Phase 3UnknownLaibin People's Hospital402023-09-012023-08-29
Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance
almonertinib - Advanced Non-small Cell Lung Cancer
Phase 3RecruitingQianfoshan Hospital982023-09-012023-09-21
Neoadjuvant Aumolertinib in Patients With AI-diagnosed EGFR-mutant High-risk Pulmonary Ground-glass Opacity.
Aumolertinib - Lung Cancer
Phase 2UnknownThe First Affiliated Hospital of Guangzhou Medical University222023-08-152024-02-06
Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation
Aumolertinib,Anlotinib - Aumolertinib, Anlotinib
Phase 2Not yet recruitingTianjin Medical University Cancer Institute and Hospital472023-03-312023-03-21

Showing 20 of 63. Sign in to see all of them.

Conditions studied

Carcinoma, Non-Small-Cell Lung (37)  ·  Lung Neoplasms (12)  ·  Brain Neoplasms (5)  ·  Meningeal Carcinomatosis (2)  ·  Adenocarcinoma (1)  ·  Carcinoma (1)  ·  Digestive System Diseases (1)  ·  Liver Diseases (1)  ·  Neoplasm, Residual (1)  ·  Radiation Pneumonitis (1)  ·  Recurrence (1)

Sponsors

Jiangsu Hansoh Pharmaceutical Co., Ltd. (8)  ·  Cancer Institute and Hospital, Chinese Academy of Medical Sciences (5)  ·  Sun Yat-sen University (4)  ·  Fudan University (3)  ·  Suzhou Suncadia Biopharmaceuticals Co., Ltd. (3)  ·  EQRx International, Inc. (2)  ·  First People's Hospital of Hangzhou (2)  ·  Fujian Cancer Hospital (2)  ·  Qianfoshan Hospital (2)  ·  Shanghai Cancer Hospital, China (2)  ·  Shanghai Chest Hospital (2)  ·  Shanghai Pulmonary Hospital, Shanghai, China (2)  ·  The First Affiliated Hospital of Guangzhou Medical University (2)  ·  Tianjin Medical University Cancer Institute and Hospital (2)  ·  Baohui Han (1)

Countries

China (49)  ·  United States (4)  ·  Bosnia and Herzegovina (1)  ·  Bulgaria (1)  ·  Moldova (1)  ·  New Zealand (1)

Top investigators

Likun Chen (2)  ·  Shun Lu, MD (2)  ·  Ying Cheng, MD (2)  ·  Bin Wang (1)  ·  Chun Huang (1)  ·  Chunxia Su (1)  ·  Conghua Xie (1)  ·  Degan Lu (1)  ·  Dingzhi Huang (1)  ·  Dingzhi Huang, M.D. (1)  ·  Fei J Zhu (1)  ·  Feng Luo (1)

Results publications

PMID 32916310, PMID 15118073, PMID 15118125, PMID 15886314, PMID 16642476, PMID 19470276, PMID 20087963, PMID 20573926, PMID 24002608, PMID 25175099, PMID 26334749, PMID 27539328, PMID 29190637, PMID 29446853, PMID 29454091, PMID 30017884, PMID 30032842, PMID 30039345, PMID 30059262, PMID 30098152, PMID 30666799, PMID 30975627, PMID 31591063, PMID 31809241, PMID 31865717, PMID 33205587, PMID 33544337, PMID 33962566, PMID 34083331, PMID 34388377, PMID 35580297, PMID 39016053, PMID 40306921, PMID 40569623, PMID 41326640, PMID 41510386, PMID 41539318, PMID 41818162, PMID 42296979, PMID 42488708